FDA and DIA to Host Public Meeting on Cross-Labeling of Combination Products

Summary

The Food and Drug Administration (FDA) and the Drug Information Association (DIA) are hosting a public meeting to gather input on cross-labeling of combination products, which are products that combine a device, drug, or biological product with an already approved product of a different type. The meeting aims to discuss the legal and public health issues surrounding this practice and inform the development of draft guidance on the topic.